2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

322. Hemophilia A and B: Clinical and Epidemiological: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Clinical Procedures, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Bispecific Antibody Therapy, Gene Therapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Pharmacology, Surgical, Women’s Health, Adverse Events, Clinical Practice (Health Services and Quality), Practice Models, Telemedicine, Diseases, Bleeding and Clotting, Bleeding Disorders, Hemophilia, Thromboembolism, Genetic Disorders, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult, Pediatric, Young Adult
PAPER

1276 Concizumab prophylaxis in children with hemophilia A or B with inhibitors: Clinical outcome assessment results from observer-reported questionnaires in the phase 3 explorer10 study

Rukhmi Bhat, MD, MS, Giancarlo Castaman, MD2, Anthony KC Chan, MBBS3, Anastasios Giakoumis4, Maria Knudsen5, Johnny Mahlangu, MMed, MBBCh6, Chiai Nagae7, Nita Radhakrishnan8, Sonata Saulyte Trakymiene9, Allison P. Wheeler, MD, MSCI10, Victor Jiménez-Yuste11
1 Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, United States
2 Careggi University Hospital, Florence, Italy
3 McMaster Children's Hospital, McMaster University, Hamilton, Canada
4 Novo Nordisk, Søborg, Denmark
5 Novo Nordisk, Søborg, Denmark
6 University of the Witwatersrand and National Health Laboratory Service, Johannesburg, South Africa
7 St Marianna University School of Medicine, Kanagawa, Japan
8 Post Graduate Institute of Child Health, Noida, India
9 Vilnius University Hospital Santaros Klinikos, Vilnius University, Vilnius, Lithuania
10 University of Washington School of Medicine, Seattle, United States
11 La Paz University Hospital-IdiPaz; Autónoma University, Madrid, Spain

Introduction

Concizumab is an anti-tissue factor pathway inhibitor (TFPI) monoclonal antibody indicated for adults and adolescents (≥12 years) with hemophilia A or B with and without inhibitors, approved by the US Food and Drug Administration, as well as the European Medicines Agency, along with other countries for once-daily, subcutaneous prophylaxis. In the phase 3 explorer10 study (NCT05135559), pediatric patients aged <12 years with hemophilia A or B with inhibitors (HAwI, HBwI) received once-daily subcutaneous concizumab prophylaxis for bleed prevention. Here, we report findings from observer-reported clinical outcome assessments following 32 weeks of concizumab prophylaxis.

Methods

A total of 45 pediatric patients aged <12 years with congenital HAwI or HBwI were screened. Of these, 33 concizumab-naïve patients were allocated to arm 1 (11 with HAwI and 22 with HBwI), 10 patients with HBwI previously treated with concizumab via compassionate use were allocated to arm 2, and 2 patients were considered screening failures. The full analysis set included all participants with inhibitors from arm 1 who had received at least one dose of concizumab and a total of at least 26 weeks of on-demand treatment within the last 52 weeks prior to enrolment, as well as arm 1 participants with HBwI regardless of previous treatment who had received at least one dose of concizumab. Parents or legally authorized representatives (LARs) of participants were asked to complete observer-reported clinical outcome assessments during site visits. Health-related quality of life (HRQoL) was assessed using the Pediatric Quality of Life Inventory Version 4.0 (PedsQL) questionnaire, with total and physical functioning scores being reported. Treatment satisfaction and convenience were assessed using a modified, abbreviated Treatment Satisfaction Questionnaire for Medication (TSQM-9), adapted for parent/LAR completion and prophylactic use. Treatment preference, including reasons for preference and strength of preference, was evaluated using the Hemophilia Patient Preference Questionnaire (H-PPQ). Changes from baseline to week 32 in PedsQL and TSQM-9 scores were summarized descriptively, and H-PPQ responses were assessed at weeks 12 and 32, with week 32 results being reported here.

Results

Observer-reported clinical outcome assessments were completed by parents/LARs (N=30) of arm 1 participants included in the full analysis set. At baseline, the mean (standard deviation; SD) PedsQL total score was 74.94 (20.03) and increased to 80.67 (17.24) at week 32, with a mean change of 5.88 (21.87). Additionally, the PedsQL physical functioning score increased from 70.77 (30.24) at baseline to 83.02 (20.87) at week 32, corresponding to a mean change of 12.32 (30.96). These results suggest an improvement in HRQoL during concizumab prophylaxis.

Treatment satisfaction and convenience also improved from baseline to week 32. The mean (SD) TSQM-9 global satisfaction score increased from 66.93 (23.27) to 81.94 (16.33), with a mean change of 13.33 (22.18). The mean (SD) TSQM-9 convenience score increased from 74.49 (18.84) to 85.97 (16.66), with a mean change of 9.64 (20.89). These results indicate a more favorable treatment experience with once-daily subcutaneous concizumab prophylaxis compared with previous on-demand treatment.

At week 32, 26 of 30 (86.7%) parents/LARs reported a preference for concizumab prophylaxis over previous on-demand treatment. Among those who preferred concizumab, 21 of 26 (80.8%) reported that their preference was “very strong”. The most frequently selected reason for preferring concizumab prophylaxis was “fewer bleeds”, reported by 21 of 26 respondents (80.8%), followed by “feels less emotional distressing”, reported by 11 of 26 respondents (42.3%).

Conclusion

In explorer10, concizumab prophylaxis was associated with improved parent/LAR-reported HRQoL, treatment satisfaction and convenience in children aged <12 years with HAwI or HBwI. Most parents/LARs preferred concizumab over previous on-demand treatment, mainly because of fewer bleeds and reduced emotional distress, supporting its potential to reduce treatment burden.

Rukhmi Bhat, MD, MS: Novo Nordisk - Consultancy (Includes expert testimony)